FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to a pharmaceutical composition for preventing the breakdown of a proton pump inhibitor in the stomach and a pharmaceutical combined composition for the above purpose. A pharmaceutical composition for preventing the breakdown of a proton pump inhibitor in the stomach which contains the following active ingredients: a proton pump inhibitor or a pharmaceutically acceptable salt thereof and an antacid selected from magnesium hydroxide, magnesium oxide and a mixture thereof, where the proton pump inhibitor or a pharmaceutically acceptable salt thereof is the magnesium salt of esomeprazole or lansoprazole, wherein the said pharmaceutical composition includes magnesium hydroxide in an amount of 6.25 parts by weight or more, when a proton pump inhibitor or a pharmaceutically acceptable salt thereof is included as a proton pump inhibitor in an amount, 1 part by weight, and wherein the said pharmaceutical composition includes magnesium oxide in an amount of 5 parts by weight or more, wherein a proton pump inhibitor or a pharmaceutically acceptable salt thereof is included as a proton pump inhibitor in an amount of 1 part by weight. A pharmaceutical combination composition for preventing the breakdown of a proton pump inhibitor in the stomach containing the following: a primary layer containing a proton pump inhibitor or a pharmaceutically acceptable salt thereof; and a secondary layer containing one selected from magnesium hydroxide, magnesium oxide and mixtures thereof, wherein the proton pump inhibitor or a pharmaceutically acceptable salt thereof is esomeprazole magnesium salt or lansoprazole, wherein the said pharmaceutical composition includes magnesium hydroxide in an amount of 6.25 parts by weight or more, wherein the proton pump inhibitor or a pharmaceutically acceptable salt thereof is included as the proton pump inhibitor in an amount of 1 part by weight, and wherein magnesium oxide is included in the said pharmaceutical composition in an amount of 5 parts by weight or more when the proton pump inhibitor or a pharmaceutically acceptable salt thereof is included as the proton pump inhibitor in an amount of 1 part by weight.
EFFECT: above group of inventions ensures increased stability of the proton pump inhibitor in the acidic environment of the stomach and rapid onset of action of the above medicinal product.
11 cl, 6 dwg, 6 tbl, 9 ex, 9 comp ex, 1 test ex
